skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study

Abstract

PurposePercutaneous isolated hepatic perfusion (PIHP) with Melphalan has been developed as a treatment for patients with isolated hepatic metastases of uveal melanoma. We discuss patient outcome and safety in a retrospective multi-centre study.Materials and MethodsBetween 2012 and 2016 18 patients with un-resectable isolated hepatic metastases of uveal melanoma received single or repeated PIHP with Melphalan (n = 35) at seven sites. Progression-free time, overall survival time (OS) and tumour response by means of RECIST 1.1 criteria were evaluated. Peri- and post-procedural adverse events (AE) were registered. Patients’ life quality was assessed using four-point scale questionnaires.ResultsOf 18 patients, initial PIHP treatment resulted in partial response (PR) in eight, stable disease (SD) in seven and progressive disease (PD) in three cases. Nine patients underwent second PIHP with PR in eight cases and PD in one case. Six patients were evaluated after third PIHP with PR in five patients and SD in one patient. Two patients received fourth PIHP with PD in both cases. Median OS was 9.6 months (range 1.6–41.0 months). Median progression-free survival time was 12.4 months (range 0.9–41.0 months) with 1-year survival of 44%. Most common post-procedural AE grade 3 and 4 were temporary leukopenia (n = 11) and thrombocytopenia (n = 8). Patients’ self-assessments showed good ratings for overallmore » health and quality of life with only slight changes after PIHP, and a high degree of satisfaction with PIHP treatment.ConclusionPIHP with Melphalan proved to be a relatively safe, minimal-invasive and repeatable treatment for patients with non-resectable hepatic metastases of uveal melanoma.« less

Authors:
;  [1];  [2];  [3];  [4];  [5]; ;  [6];  [7];  [8];  [9];  [1]
  1. University Hospital Frankfurt, Department of Diagnostic and Interventional Radiology (Germany)
  2. University Hospital Frankfurt, Department of Anesthesiology, Intensive-Care Medicine and Pain Therapy (Germany)
  3. Universitätsmedizin Berlin, Department of Diagnostic and Interventional Radiology, Campus Charité Mitte (Germany)
  4. Brüderkrankenhaus Trier, Department of Diagnostic and Interventional Radiology (Germany)
  5. Evangelisches Krankenhaus Göttingen-Weende gGmbH, Department of Diagnostic and Interventional Radiology (Germany)
  6. Asklepios Klinik Barmbek, Department of Diagnostic and Interventional Radiology (Germany)
  7. Medizinische Hochschule Hannover, Department of Diagnostic and Interventional Radiology (Germany)
  8. Medizinische Hochschule Hannover, Department of Gastroenterology, Hepatology and Endocrinology (Germany)
  9. Heidelberg University Hospital, Department of Diagnostic and Interventional Radiology (Germany)
Publication Date:
OSTI Identifier:
22645171
Resource Type:
Journal Article
Resource Relation:
Journal Name: Cardiovascular and Interventional Radiology; Journal Volume: 40; Journal Issue: 6; Other Information: Copyright (c) 2017 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE); http://www.springer-ny.com; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; AUGER ELECTRON SPECTROSCOPY; LEUKOPENIA; LIVER; MELANOMAS; METASTASES; PATIENTS; SAFETY; SURVIVAL TIME

Citation Formats

Vogl, Thomas J., E-mail: t.vogl@em.uni-frankfurt.de, Koch, Silvia A., E-mail: silvia.koch@web.de, Lotz, Gösta, E-mail: goesta.lotz@kgu.de, Gebauer, Bernhard, E-mail: bernhard.gebauer@charite.de, Willinek, Winfried, E-mail: w.willinek@bk-trier.de, Engelke, Christoph, E-mail: engelke@ekweende.de, Brüning, Roland, E-mail: r.bruening@asklepios.com, Zeile, Martin, E-mail: m.zeile@asklepios.com, Wacker, Frank, E-mail: wacker.frank@mh-hannover.de, Vogel, Arndt, E-mail: vogel.arndt@mh-hannover.de, Radeleff, Boris, E-mail: boris.radeleff@med.uni-heidelberg.de, and Scholtz, Jan-Erik, E-mail: janerikscholtz@gmail.com. Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study. United States: N. p., 2017. Web. doi:10.1007/S00270-017-1588-2.
Vogl, Thomas J., E-mail: t.vogl@em.uni-frankfurt.de, Koch, Silvia A., E-mail: silvia.koch@web.de, Lotz, Gösta, E-mail: goesta.lotz@kgu.de, Gebauer, Bernhard, E-mail: bernhard.gebauer@charite.de, Willinek, Winfried, E-mail: w.willinek@bk-trier.de, Engelke, Christoph, E-mail: engelke@ekweende.de, Brüning, Roland, E-mail: r.bruening@asklepios.com, Zeile, Martin, E-mail: m.zeile@asklepios.com, Wacker, Frank, E-mail: wacker.frank@mh-hannover.de, Vogel, Arndt, E-mail: vogel.arndt@mh-hannover.de, Radeleff, Boris, E-mail: boris.radeleff@med.uni-heidelberg.de, & Scholtz, Jan-Erik, E-mail: janerikscholtz@gmail.com. Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study. United States. doi:10.1007/S00270-017-1588-2.
Vogl, Thomas J., E-mail: t.vogl@em.uni-frankfurt.de, Koch, Silvia A., E-mail: silvia.koch@web.de, Lotz, Gösta, E-mail: goesta.lotz@kgu.de, Gebauer, Bernhard, E-mail: bernhard.gebauer@charite.de, Willinek, Winfried, E-mail: w.willinek@bk-trier.de, Engelke, Christoph, E-mail: engelke@ekweende.de, Brüning, Roland, E-mail: r.bruening@asklepios.com, Zeile, Martin, E-mail: m.zeile@asklepios.com, Wacker, Frank, E-mail: wacker.frank@mh-hannover.de, Vogel, Arndt, E-mail: vogel.arndt@mh-hannover.de, Radeleff, Boris, E-mail: boris.radeleff@med.uni-heidelberg.de, and Scholtz, Jan-Erik, E-mail: janerikscholtz@gmail.com. Thu . "Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study". United States. doi:10.1007/S00270-017-1588-2.
@article{osti_22645171,
title = {Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study},
author = {Vogl, Thomas J., E-mail: t.vogl@em.uni-frankfurt.de and Koch, Silvia A., E-mail: silvia.koch@web.de and Lotz, Gösta, E-mail: goesta.lotz@kgu.de and Gebauer, Bernhard, E-mail: bernhard.gebauer@charite.de and Willinek, Winfried, E-mail: w.willinek@bk-trier.de and Engelke, Christoph, E-mail: engelke@ekweende.de and Brüning, Roland, E-mail: r.bruening@asklepios.com and Zeile, Martin, E-mail: m.zeile@asklepios.com and Wacker, Frank, E-mail: wacker.frank@mh-hannover.de and Vogel, Arndt, E-mail: vogel.arndt@mh-hannover.de and Radeleff, Boris, E-mail: boris.radeleff@med.uni-heidelberg.de and Scholtz, Jan-Erik, E-mail: janerikscholtz@gmail.com},
abstractNote = {PurposePercutaneous isolated hepatic perfusion (PIHP) with Melphalan has been developed as a treatment for patients with isolated hepatic metastases of uveal melanoma. We discuss patient outcome and safety in a retrospective multi-centre study.Materials and MethodsBetween 2012 and 2016 18 patients with un-resectable isolated hepatic metastases of uveal melanoma received single or repeated PIHP with Melphalan (n = 35) at seven sites. Progression-free time, overall survival time (OS) and tumour response by means of RECIST 1.1 criteria were evaluated. Peri- and post-procedural adverse events (AE) were registered. Patients’ life quality was assessed using four-point scale questionnaires.ResultsOf 18 patients, initial PIHP treatment resulted in partial response (PR) in eight, stable disease (SD) in seven and progressive disease (PD) in three cases. Nine patients underwent second PIHP with PR in eight cases and PD in one case. Six patients were evaluated after third PIHP with PR in five patients and SD in one patient. Two patients received fourth PIHP with PD in both cases. Median OS was 9.6 months (range 1.6–41.0 months). Median progression-free survival time was 12.4 months (range 0.9–41.0 months) with 1-year survival of 44%. Most common post-procedural AE grade 3 and 4 were temporary leukopenia (n = 11) and thrombocytopenia (n = 8). Patients’ self-assessments showed good ratings for overall health and quality of life with only slight changes after PIHP, and a high degree of satisfaction with PIHP treatment.ConclusionPIHP with Melphalan proved to be a relatively safe, minimal-invasive and repeatable treatment for patients with non-resectable hepatic metastases of uveal melanoma.},
doi = {10.1007/S00270-017-1588-2},
journal = {Cardiovascular and Interventional Radiology},
number = 6,
volume = 40,
place = {United States},
year = {Thu Jun 15 00:00:00 EDT 2017},
month = {Thu Jun 15 00:00:00 EDT 2017}
}